Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

January 18, 2021January 18, 2021

Risankizumab for 12 Weeks Leads to Remission in Crohn’s Trials

Crohn's Disease, News

Treatment with risankizumab for 12 weeks (three months) induced both clinical and endoscopic remission in people with Crohn’s disease, a type of inflammatory bowel disease (IBD), new Phase 3 ... Read more

January 4, 2021January 4, 2021

EU Reviewing Zeposia as Ulcerative Colitis Treatment for Adults

IBD News, News, Ulcerative colitis

The anti-inflammatory medication Zeposia (ozanimod) is under review in the European Union as a treatment for adults with moderately to severely active ulcerative colitis. The European Medicines Agency has ... Read more

October 12, 2020October 12, 2020

Wearable Sweat Sensor Could Help Monitor IBD Flares, Study Finds

News

A new wearable sensor that measures the levels of inflammatory molecules in sweat could be used to monitor flares in people with inflammatory bowel disease (IBD), according to a ... Read more

September 30, 2020September 30, 2020

Compound from Blueberries Has Potential for Treating IBD, Study Suggests

IBD News, News

Pterostilbene (PSB), a compound found in blueberries, can reduce the inflammatory activity of immune cells and limit colon inflammation in mice, a new study shows. The findings suggest that ... Read more

June 22, 2020June 22, 2020

Stem Cell-related Abnormalities May Predict Recurrence in Crohn’s Disease

Crohn's Disease, News

Abnormalities in intestinal stem cell niches may predict recurrence in Crohn’s disease, a new study suggests. These irregularities may result from problems with mitochondria — the so-called powerhouse of ... Read more

May 18, 2020May 18, 2020

Early Phase 2 Trial Data Support Safety, Efficacy of BBT-401 for Ulcerative Colitis

News, Ulcerative colitis

People with ulcerative colitis may benefit from the experimental oral therapy BBT-401, suggest early data from an ongoing Phase 2 clinical trial that also supports its good safety profile. BBT-401 ... Read more

May 11, 2020May 11, 2020

Entyvio At-home Injection Approved in Europe to Treat Adults With IBD

Crohn's Disease, News, Ulcerative colitis

The European Commission has approved a subcutaneous (under-the-skin) formulation of Entyvio (vedolizumab) for use as maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). ... Read more

April 13, 2020April 13, 2020

Etrasimod in Controlled Release Seen to Limit Heart Rate Changes, May Be Added to Trials

News

A controlled-release version of etrasimod could limit the changes in heart rate linked to an initial dose of this investigational medication, according to topline clinical trial data announced by ... Read more

March 16, 2020March 16, 2020

Immunosuppressive Therapy Does Not Increase Vaginal Cancer Risk, Study Finds

News

Therapies that suppress the immune system do not increase the risk of vulvar or vaginal cancer in women with inflammatory bowel disease (IBD), a new study has found. The ... Read more

January 8, 2020January 8, 2020

People With IBD At Higher Risk Of Serious Viral Infections, Study Suggests

News

Adults with inflammatory bowel disease (IBD) have an increased risk of serious viral infections compared to the general population, a study suggests. This risk was found to be highest ... Read more